Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Financial Results (May 11, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 11, 2026
Period End
May 11, 2026
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Nov ’19Nov ’19
  3. Leadership change8-K · Feb ’23Feb ’23
  4. Leadership change8-K · Mar ’25Mar ’25

Summary

Summary of the 8-K filed May 11, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. (Nasdaq: HALO) furnished a press release under Item 2.02 reporting first quarter 2026 results for the quarter ended March 31, 2026.

Total revenue was $376.7 milliona, up 42% year over year from $264.9 million, driven by royalty revenue of $240.7 million (up 43% from $168.2 million) and product sales, net, of $130.4 million. GAAP net income was $150.0 million and GAAP diluted EPS was $1.22, compared with $0.93 a year earlier. Non-GAAP diluted EPS was $1.60, versus $1.11.

Adjusted EBITDA was $229.5 millionb, including $11.2 million of intellectual property litigation costs tied to the company's patent case against Merck. Cash, cash equivalents, restricted cash and marketable securities rose to $320.9 million at March 31, 2026, from $145.4 million at December 31, 2025, which the company attributed primarily to operating cash generation. The company reiterated its full-year 2026 guidance: total revenue of $1.710 to $1.810 billion, royalty revenue of $1.130 to $1.170 billion, adjusted EBITDA of $1.125 to $1.205 billion, and non-GAAP diluted EPS of $7.75 to $8.25.

The guidance includes approximately $60 millionc of investment related to new Hypercon and Surf Bio activities. The company also announced a new share repurchase program of up to $1 billion of common stock through December 31, 2028, with at least $400 million expected to be repurchased in 2026. The quarter also featured new partnering activity: a Vertex Hypercon agreement with a $15 million upfront payment, a GSK ENHANZE multi-target collaboration, and an Oruka Hypercon agreement.

The company also highlighted FDA approval of VYVGART Hytrulo for all serotypes of generalized myasthenia gravis and positive Phase 3 data in ocular myasthenia gravis. The filing notes that results and partner milestones are forward-looking in part and subject to risks described in the company's Form 10-K and Form 10-Q.

Key Highlights

  1. Total revenue of $376.7 million, up 42% year over year from $264.9 million; royalty revenue of $240.7 million, up 43%.
  2. GAAP diluted EPS of $1.22 versus $0.93 a year earlier; non-GAAP diluted EPS of $1.60 versus $1.11.
  3. Operating income of $184.5 million versus $141.5 million; net income of $150.0 million versus $118.1 million.
  4. Adjusted EBITDA of $229.5 million, which excludes $11.2 million of intellectual property litigation costs related to the Merck patent case.
  5. Cash, cash equivalents, restricted cash and marketable securities increased to $320.9 million from $145.4 million at December 31, 2025.
  6. New $1 billion share repurchase program through December 31, 2028, with at least $400 million expected to be bought back in 2026.
  7. 2026 guidance reiterated: total revenue of $1.710 to $1.810 billion and non-GAAP diluted EPS of $7.75 to $8.25.

Frequently Asked Questions

  1. How did Halozyme's first quarter 2026 revenue compare with the prior year?

    Total revenue was $376.7 million, compared with $264.9 million in the first quarter of 2025. The filing attributes the increase primarily to royalty revenue growth and higher product sales. Royalty revenue was $240.7 million, up from $168.2 million.

  2. What is the status of the company's 2026 financial guidance?

    Halozyme reiterated its 2026 guidance ranges, last provided on February 17, 2026. These are total revenue of $1.710 to $1.810 billion, royalty revenue of $1.130 to $1.170 billion, adjusted EBITDA of $1.125 to $1.205 billion, and non-GAAP diluted EPS of $7.75 to $8.25. The EPS guidance includes approximately $60 million of new Hypercon and Surf Bio investment and does not reflect potential future share repurchases.

  3. What did the company announce about share repurchases?

    Halozyme announced a program to repurchase up to $1 billion of its outstanding common stock by December 31, 2028. The company expects to buy back at least $400 million of shares in 2026.

  4. Why did costs rise in the quarter?

    Cost of sales rose to $79.2 million from $48.4 million, mainly due to higher bulk rHuPH20 sales. Amortization of intangibles increased to $29.5 million from $17.8 million following the Elektrofi acquisition in November 2025. SG&A rose to $57.9 million from $42.4 million, reflecting consulting and professional fees, including patent litigation costs, the Elektrofi and Surf Bio acquisitions, and higher compensation.

  5. What new partnering deals were announced?

    In April 2026, Halozyme signed a Hypercon agreement with Vertex covering up to three targets, with a $15 million upfront payment. In May 2026, it entered a GSK collaboration for ENHANZE covering multiple oncology targets, and an Oruka Therapeutics Hypercon agreement for ORKA-001 and one additional target. The filing states that these deals include upfront, milestone and royalty payments, but does not disclose the GSK or Oruka upfront amounts.